Evaluation the effect of adding methylprednisolone to mitoxantrone on progressive multiple sclerosis treatment
Not Applicable
- Conditions
- Multiple Sclerosis.Demyelinating diseases of the central nervous system
- Registration Number
- IRCT201107145943N3
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
presence of progressive MS, age between 20 to 50
Exclusion criteria: Age below 20 or above 50, Immune deficiency, cancer, Pregnancy or breast feeding, Renal or heart failure, Leukopenia during the injection (the reduction of neutrophils to less than 1500/ml), having received corticosteroids within 6 months before the trial
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MRI plaque numbers. Timepoint: 6 months and 1 year after the intervention. Method of measurement: Based on MRI imaging.;Expanded Disability Status Scale (EDSS). Timepoint: 6 months and 1 year after the intervention. Method of measurement: Based on definit idex.
- Secondary Outcome Measures
Name Time Method